Sarepta signs agreement with Hansa Biopharma for imlifidase
Sarepta Therapeutics signs agreement with Hansa Biopharma for imlifidase. This exclusive worldwide license enables Sarepta to develop and promote imlifidase as a pre-treatment for gene therapy in [...]
